Stock·NYSE·Industrials
Johnson Controls International (JCI)
- Market cap
- $88.12B
- P/E
- 42.79
- Dividend yield
- 1.08%
- Street target
- $166.00median of 22 analysts
- 52-week range
- $107.84 $160.41
The short version
Where JCI stands today, in four lines, and what CleaRank Financial AI makes of it.
JCI at a glance
Johnson Controls International (JCI): Hold, 59/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($139.34 and $147.49).
- Earnings JCI beat estimates in 7 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $40.8M and bought $1.0M over the last 18 months.
- Valuation P/E of 42.8 against 34.0 for the Industrials sector: a premium to peers (+26%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Johnson Controls International (JCI) Hold, with a model score of 59/100.
The earnings record lifts the score most: it beat estimates in 7 of its last 7 reports and the latest report beat the estimate by 9.23%. Valuation holds it back most: the P/E of 42.79 is 25.9% above the sector median (a premium to peers). The trend is mixed: JCI trades 1.37% below its 50-day average of $147.49 and 4.40% above its 200-day average of $139.34. Over the past year the price rose 33.01%.
Only on CleaRank
Figures we compute ourselves from JCI's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $145.47 is 1.4% below the 50-day simple moving average of $147.49.Price above its 200-day average ›
The price is 4.4% above the 200-day simple moving average of $139.34.50-day average above the 200-day ›
The 50-day average ($147.49) is 5.9% above the 200-day average ($139.34), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 72% of its 52-week range, between $107.84 and $160.41.
JCI share price
Pick a period: each tab shows how far JCI has moved over it, to the last close.
Today's trading
Where JCI sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 42.79 is 25.9% above the Industrials median of 34.0.P/S below the sector median ›
The price-to-sales ratio of 3.58 is 10.6% below the sector median of 4.0.Profitable over the last 12 months ›
Net income over the last 12 months was $2.2B on revenue of $25.0B, a net margin of 8.7%.Beat estimates in most recent reports ›
JCI beat the EPS estimate in 7 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 1.08%, or $1.57 a share a year.
Key statistics
The headline figures for JCI.
As of October 17, 2026, JCI trades at $145.47, with a market value of $88.12B, a P/E ratio of 42.79 and a dividend yield of 1.08%.
What the numbers say
CleaRank Financial AI's reading of JCI's valuation, growth and risks.
JCI carries a trailing P/E of 42.79, which is 25.9% above the Industrials median of 34.0. The peer comparison on this page puts the P/E at a premium to peers. Its price-to-sales ratio of 3.58 is 10.5% below the sector median of 4.0, and the company's market capitalisation stands at $88.1B.
Growth trails the sector: revenue grew 9.30% in the latest year, against a sector median of 11.7%. JCI keeps a net margin of 14.32% and an operating margin of 15.88%. It generates a return on equity of 14.33%, below the sector median of 17.8%. Rounding out the fundamentals, JCI reports debt-to-equity of 0.70 and a trailing dividend yield of 1.08% ($1.57 a share a year).
JCI's latest report, released on July 29, 2026, topped the estimate by 9.23%: EPS came in at $1.42 versus an expected $1.30. Investors responded positively, as the stock climbed 3.20% in the next session.
Across its last 7 reports, JCI beat the estimate every time; even so, 1 of those 7 beats was followed by a lower share price the next session. Looking ahead, analysts expect EPS of $5.07 this fiscal year (growth of 34.8%) and $6.10 the year after (growth of 20.3%).
With a P/E of 42.79 sitting 25.9% above the sector median, JCI is priced as a premium to peers, which means softer results would be judged against a demanding bar. The stock's average daily move is 1.92%.
JCI against the Industrials sector
How JCI compares with the median Industrials stock CleaRank tracks.
Price to earnings vs sector: JCI trades at a significant premium to sector peers (+26%), suggesting market expectations for superior growth or market position.
Return vs XLI: Since May 6, 2025, JCI has gained 63.8% against a gain of 25.7% for XLI.
Performance against XLI
JCI and the Industrials sector fund over the same days.
Revenue and earnings
How much JCI sells, and how much of it becomes profit.
Revenue growth: Revenue grew 2.8% in FY2025 to $23.6B, from $23.0B a year earlier.
Profit margin: The net margin was 14.9% in FY2025, up from 8.3% the year before.
Profitable: JCI earned $3.5B in FY2025.
Earnings reality check
Did JCI beat what analysts expected, and how did the stock react?
Earnings record: JCI beat the analyst estimate in 7 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 29, 2026after close | $1.30 | $1.42 | +9.23% | +3.20% | +10.21% |
| May 6, 2026after close | $1.12 | $1.19 | +6.25% | -2.72% | +0.46% |
| Feb 4, 2026after close | $0.84 | $0.89 | +5.95% | +2.34% | +8.86% |
| Jul 29, 2025after close | $1.01 | $1.05 | +3.96% | +0.76% | +1.55% |
| May 7, 2025after close | $0.80 | $0.82 | +2.50% | +1.66% | +7.35% |
| Feb 5, 2025after close | $0.59 | $0.64 | +8.47% | +2.31% | +3.51% |
| Nov 6, 2024after close | $1.25 | $1.28 | +2.40% | +0.54% | +5.20% |
As of October 17, 2026, JCI has beaten the analyst EPS estimate in 7 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 29, 2026, came in 9.23% above the estimate and the stock moved +3.20% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 42.6, in neutral territory.RSI above 50 ›
An RSI of 42.6 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of JCI
The score, the reasoning behind it, and what could move the price next.
Johnson Controls International (JCI) is giving a mixed trend read. Trading at $145.47, the stock is 1.37% below its 50-day average of $147.49, yet 4.40% above its 200-day average of $139.34. Shares sit near the top of their 52-week range, 9.31% under the $160.41 high and 34.89% over the $107.84 low. The 50-day average is 5.85% above the 200-day, so the moving averages have yet to catch up with the softer price.
The price is up over each of these periods: 3.56% over the past month, 3.57% over the past three months and 33.01% over the past year. The 14-day RSI of 42.6 is in the neutral zone, and the MACD line is positive.
Earnings beat ›
The July 29, 2026 report beat the EPS estimate by 9.23%, and the share price rose 3.20% in the first session after it.
Source: Earnings report, July 29, 2026Rating reaffirmed ›
B of A Securities kept its Buy rating on October 8, 2026.
Source: Analyst action, B of A Securities, October 8, 2026
New analyst coverage ›
Wells Fargo started coverage at Overweight on September 25, 2026.
Source: Analyst action, Wells Fargo, September 25, 2026
- Keep an eye on the two closest levels: the 50-day SMA at $147.49 sits above the price, and the 200-day SMA at $139.34 sits below it.
- The 14-day RSI reads 42.6, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- The share price rose 3.20% in the first session after the July 29, 2026 report. JCI has beaten estimates in 7 of its last 7 reports.
JCI sits above its 200-day average of $139.34 but below its 50-day average of $147.49, so the trend is mixed. A close above the 50-day would turn both signals up, while a close below the 200-day would turn both down. On the way up, the first level is the 50-day SMA at $147.49; on the way down, the first is the 200-day SMA at $139.34.
Technical indicators
Momentum and trend for JCI, from its daily closes.
As of October 17, 2026, with JCI at $145.47, its 14-day RSI is 42.6 (neutral territory), its 50-day simple moving average is $147.49 and its 200-day is $139.34.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What JCI moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, JCI's 1-year correlation of daily returns is +0.62 with S&P 500 (SPY), +0.60 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and +0.11 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
12 of 22 analysts rate it a buy or strong buy, 8 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $166.00 is 14.1% above the price.More buy ratings than three months ago ›
12 of 22 rate it a buy now, against 11 of 21 three months ago.
JCI Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | B of A Securities | Maintains | Buy |
| Sep 25, 2026 | Wells Fargo | Initiates | Overweight |
| Sep 2, 2026 | Morgan Stanley | Maintains | Overweight |
| Aug 14, 2026 | Bernstein | Maintains | Outperform |
| Jul 30, 2026 | Citigroup | Maintains | Neutral |
| Jul 30, 2026 | RBC Capital | Maintains | Sector Perform |
As of October 17, 2026, 22 Wall Street analysts cover JCI: 12 rate it a buy or strong buy, 8 a hold and 2 a sell or strong sell. Their 12-month price targets range from $129.00 to $193.00, with a median of $166.00, 14.1% above the price of $145.47.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
JCI trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from JCI's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much JCI tends to move, against the market and on its own.
The long record
JCI's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.92% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 41.3%, from December 2021 to July 2022, regained by September 2024.Most 1-year holds ended higher ›
64% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $41,346, against $42,055 in the S&P 500 (SPY).
JCI Drawdowns & Recovery
As of October 17, 2026, JCI's worst peak-to-trough fall over the last 10 years with dividends reinvested was -41.3% (December 2021 to July 2022); it regained that peak by September 2024, 26 months after the low, and 64% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into JCI in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: JCI trailed the S&P 500 over this period: $41,346 against $42,055.
A $10,000 investment in JCI in October 2016 would be worth about $41,346 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to JCI, and which have not.
Strongest month, November: an average of +5.84%, up in 8 of 10 years.
Weakest month, March: an average of -3.27%, up in 5 of 10 years.
This month, October: has averaged +0.70%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, JCI's strongest calendar month has been November (average +5.84%, up in 8 of 10 years) and its weakest March (average -3.27%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in JCI, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in JCI today could grow to about $22,892 by 2036 in the base case, with a 90th-percentile outcome near $72,214 and a 10th-percentile outcome around $7,257. The simulation models price only; at today's 1.08% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
JCI Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $203 for JCI by 2030 in the base case, from $145 today (1.4x over 4 years). The 10th-percentile path ends near $97.97. These are outcomes of a Monte Carlo simulation run on JCI's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $110 | $158 | $227 | |
| 2028 | $103 | $172 | $287 | |
| 2029 | $99.40 | $187 | $350 | |
| 2030 | $97.97 | $203 | $419 | |
| 2031 | $97.68 | $220 | $496 |
Method: a lognormal simulation of JCI's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
JCI insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.0M on the open market and sold $40.8M.
As of October 17, 2026, JCI insiders reported 19 open-market sales worth $40.8M and 1 open-market purchase worth $1.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 19, 2026 | Pierre E Cohade
Director
|
Sell | 3.3K | $487.7K |
| Aug 4, 2026 | Lei Zhang Schlitz
Officer
|
Sell | 23.4K | $3.6M |
| Jun 9, 2026 | Todd M Grabowski
Officer
|
Sell | 1.8K | $263.2K |
| Jun 8, 2026 | Irene M Esteves
Director
|
Grant | 937 | - |
| May 14, 2026 | Todd M Grabowski
Officer
|
Sell | 4.3K | $621.9K |
| May 8, 2026 | Lei Zhang Schlitz
Officer
|
Sell | 88.8K | $12.5M |
| May 8, 2026 | Lei Zhang Schlitz
Officer
|
Option | 62.8K | $3.9M |
| Mar 4, 2026 | Timothy M Archer
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Pierre E Cohade
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Webster Roy Dunbar
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Gretchen R Haggerty
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Ayesha Khanna
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Seetarama Swamy Kotagiri
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Carl Juergen Tinggren
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | Mark P Vergnano
Director
|
Grant | 1.3K | - |
| Mar 4, 2026 | John D Young
Director
|
Grant | 1.3K | - |
| Feb 23, 2026 | Daniel C Mcconeghy
Officer
|
Sell | 3.6K | $513.2K |
| Feb 6, 2026 | Todd M Grabowski
Officer
|
Sell | 6.1K | $816.1K |
| Feb 5, 2026 | Mark P Vergnano
Director
|
Buy | 7.7K | $1.0M |
| Feb 5, 2026 | Mark P Vergnano
Director
|
Grant | 7.7K | - |
| Jan 26, 2026 | Susan Mckee Hughes
Officer
|
Grant | 23.2K | - |
| Dec 10, 2025 | John Donofrio
General Counsel
|
Sell | 21.6K | $2.5M |
| Dec 5, 2025 | John Donofrio
General Counsel
|
Grant | 21.8K | $2.5M |
| Dec 5, 2025 | Todd M Grabowski
Officer
|
Grant | 1.7K | $197.8K |
| Dec 5, 2025 | Richard Lek
Officer
|
Grant | 1.2K | $141.3K |
| Dec 5, 2025 | Daniel C Mcconeghy
Officer
|
Grant | 4.9K | $565.4K |
| Dec 5, 2025 | Anuruddha Rathninde
Officer
|
Grant | 16.8K | $1.9M |
| Dec 5, 2025 | Lei Zhang Schlitz
Officer
|
Grant | 27.2K | $3.1M |
| Dec 5, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Grant | 4.9K | $554.1K |
| Dec 1, 2025 | John Donofrio
General Counsel
|
Grant | 4.8K | - |
| Dec 1, 2025 | Todd M Grabowski
Officer
|
Grant | 3.8K | - |
| Dec 1, 2025 | Brandt Julie M Heuer
President
|
Grant | 4.4K | - |
| Dec 1, 2025 | Richard Lek
Officer
|
Grant | 2.2K | - |
| Dec 1, 2025 | Daniel C Mcconeghy
Officer
|
Grant | 1.1K | - |
| Dec 1, 2025 | Anuruddha Rathninde
Officer
|
Grant | 3.7K | - |
| Dec 1, 2025 | Christopher M Scalia
Officer
|
Grant | 4.1K | - |
| Dec 1, 2025 | Lei Zhang Schlitz
Officer
|
Grant | 6.0K | - |
| Dec 1, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Grant | 7.2K | - |
| Dec 1, 2025 | Joakim Weidemanis
Chief Executive Officer
|
Grant | 26.1K | - |
| Nov 21, 2025 | Lei Zhang Schlitz
Officer
|
Sell | 32.0K | $3.6M |
| Nov 13, 2025 | Jean S. Blackwell
Director
|
Grant | 4.9K | - |
| Nov 6, 2025 | Lei Zhang Schlitz
Officer
|
Sell | 10.5K | $1.3M |
| Sep 3, 2025 | Daniel C Mcconeghy
Officer
|
Sell | 5.9K | $625.6K |
| Sep 3, 2025 | Daniel C Mcconeghy
Officer
|
Option | 5.9K | $470.6K |
| Sep 2, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $149.4K |
| Aug 1, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $147.4K |
| Jul 14, 2025 | Christopher M Scalia
Officer
|
Grant | 23.5K | $2.5M |
| Jul 1, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $149.1K |
| Jun 6, 2025 | Anuruddha Rathninde
President
|
Sell | 15.0K | $1.5M |
| Jun 2, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $143.5K |
| May 23, 2025 | George R Oliver Sr
Director
|
Grant | 360 | - |
| May 9, 2025 | George R Oliver Sr
Director
|
Sell | 100.0K | $9.2M |
| May 9, 2025 | George R Oliver Sr
Director
|
Grant | 2.6K | - |
| May 8, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Sell | 28.3K | $2.6M |
| May 8, 2025 | Marc Vandiepenbeeck
Chief Financial Officer
|
Option | 23.0K | $1.0M |
| May 1, 2025 | Nathan D Manning
Officer
|
Sell | 1.4K | $123.6K |
Source: TwelveData, from reported insider filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.